Live Feeds
● TRACKER Updated 22d ago · 48 sources tracked

‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight

Eli Lilly's experimental weight loss drug retatrutide has demonstrated significant weight loss results in phase 3 clinical trials, with patients losing up to 24.2% of their body weight. Even at the lowest dose, trial patients lost 12.7% of their weight. The drug targets three metabolic pathways and increases caloric expenditure. Medical professionals are evaluating potential drawbacks such as frailty, lost strength, and difficulty eating.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (48)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Retatrutide trial patients lost 12.7% of their weight even on the lowest dose.
  • ✓ Retatrutide targets three hormone receptors involved in metabolic regulation.
  • ✓ The drug shows potential for pain relief alongside substantial fat loss.
  • ✓ Retatrutide achieves weight loss results of up to 24.2%.
🛡️ Source Corroboration: 48 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Newly reported details on retatrutide's phase 3 trial results, including lower-dose efficacy, have emerged.

Live updates

  1. Eli Lilly's retatrutide shows 12.7%-24.2% weight loss in trials

    Eli Lilly's experimental weight loss drug retatrutide has demonstrated significant weight loss results in phase 3 clinical trials, with patients losing up to 24.2% of their body weight. Even at the lowest dose, trial patients lost 12.7% of their weight. The drug targets three metabolic pathways and increases caloric expenditure. Medical professionals are evaluating potential drawbacks such as frailty, lost strength, and difficulty eating.

    Why it matters

    The retatrutide trials are part of a larger effort to develop effective treatments for obesity. Previous phase 3 trials have shown average weight loss near 28 percent, although results vary across studies. The drug's potential for pain relief alongside substantial fat loss is also being evaluated.

    What is confirmed

    • Retatrutide trial patients lost 12.7% of their weight even on the lowest dose.
    • Retatrutide targets three hormone receptors involved in metabolic regulation.
    • The drug shows potential for pain relief alongside substantial fat loss.
    • Retatrutide achieves weight loss results of up to 24.2%.

    Still unconfirmed

    • An FDA filing for retatrutide is due in 2027.

    What to watch next

    • FDA approval decision
    • Further details on potential side effects
    • Comparative trials with other weight loss treatments
    Sources used for this update (4)
    1. beautybypeptides.com — Retatrutide Phase 3 Results: Up to 22.6% Weight Loss and an ...
    2. www.dietglp.com — UBT251: Novo Nordisk's Triple Agonist, Results and Phase 3
    3. glp3planner.com — GLP-3 vs GLP-1: Triple vs Single Agonist Comparison Chart ...
    4. glp3planner.com — How Does Retatrutide Work? The Triple Agonist Mechanism ...
    confidence 90%
  2. Retatrutide Trials Show Weight Loss Near 28 Percent

    Phase 3 clinical trial results for Eli Lilly's experimental triple-agonist drug retatrutide demonstrate average weight loss near 28 percent in the largest trial. Across five positive phase 3 trials, the triple-action medication targets three metabolic pathways and increases caloric expenditure to achieve results that outpace earlier therapies. While patients experience significant reductions in body mass, medical professionals are debating potential drawbacks such as frailty, lost strength, and difficulty eating. The drug also shows potential for pain relief alongside substantial fat loss in ongoing evaluations.

    Why it matters

    Retatrutide is a triple-agonist therapy that targets three hormone pathways simultaneously, distinguishing it from older single- or dual-pathway treatments. Previous data indicated adults with obesity lost 25 percent of their body weight over 80 weeks, while diabetic patients achieved a 20.8 percent reduction. As clinical trials advance, the medical community continues to assess the balance between extreme fat loss and patient safety.

    What is confirmed

    • Retatrutide targets three hormone pathways to drive significant weight loss.
    • Clinical trials show average weight loss near 28 percent in the largest study.
    • The experimental drug increases caloric expenditure.

    Still unconfirmed

    • Retatrutide leads to nearly triple the weight loss of other drugs in the same time period.
    • The drug is being evaluated for pain relief in addition to weight loss.

    What to watch next

    • Regulatory approval decisions for retatrutide
    • Further peer-reviewed publications from the TRIUMPH trial series
    • Clinical guidance on managing frailty and strength loss during treatment
    Sources used for this update (6)
    1. www.womenshealthmag.com — A New, Stronger GLP-1 Is Currently in Clinical Trials. Here's ...
    2. thepeptideinstitute.org — Retatrutide phase 3 results are in. Here is what the TRIUMPH ...
    3. scitechdaily.com — New Triple-Action Drug Helps People With Diabetes Lose Up to ...
    4. nowpatient.com — Retatrutide: The most powerful weight-loss drug yet? New ...
    5. worldhealth.net — Retatrutide for Weight Loss: The Rising Star of GLP-1 Drugs
    6. www.medscape.com — Beyond the Scale: Weight-Loss Drugs Aren’t a Quick Fix
    confidence 100%
  3. No new data on retatrutide weight loss trials

    Current data for Eli Lilly's retatrutide shows the triple-agonist therapy achieves significant weight loss by targeting three hormone pathways. Adults with obesity but without diabetes lost 25 percent of their body weight over 80 weeks, while those with type 2 diabetes saw a 20.8 percent reduction and improved blood sugar control. These results outpaced a 3.9 percent weight drop in the placebo group. The drug increases caloric expenditure to drive these outcomes.

    Why it matters

    Retatrutide differs from existing treatments by utilizing a triple-agonist approach rather than single or dual hormone targets. This mechanism aims to push weight loss figures beyond current pharmaceutical standards. The drug remains an investigational therapy in late-stage clinical trials.

    What is confirmed

    • Adults with obesity without diabetes experienced a 25 percent weight reduction over 80 weeks.
    • Participants with type 2 diabetes saw a 20.8 percent weight reduction over 80 weeks.
    • The placebo group in the obesity trial experienced a 3.9 percent weight drop.

    What to watch next

    • Publication of results for the lowest dose trial group
    • FDA regulatory filing dates for retatrutide
    • Comparative data against existing dual-hormone treatments
    Sources used for this update (3)
    1. jen.jiji.com — Autoimmune liver diseases, new strategy with nanocarriers in Italian study
    2. jen.jiji.com — Italy in the grip of bad weather, disturbance arriving with rain and downpours: Betti's (Cnr) forecasts
    3. en.wiktionary.org — triple - Wiktionary, the free dictionary
    confidence 100%
  4. Retatrutide Trials Show Record Weight Loss and Triple Hormone Action

    Eli Lilly's experimental weekly injection retatrutide achieves high weight loss figures in late-stage clinical trials by targeting three hormone pathways instead of one or two. Adults with obesity but without diabetes achieved a 25 percent reduction in body weight over an eighty-week period compared to a 3.9 percent drop for those on a placebo. Meanwhile, participants with type 2 diabetes saw a 20.8 percent reduction over the same timeframe while also experiencing improved blood sugar control. The investigational triple-agonist therapy accelerates caloric expenditure, pushing clinical trial outcomes beyond existing single-hormone and dual-hormone treatments.

    Why it matters

    Retatrutide sets itself apart from current therapies by activating three distinct hormone receptors simultaneously. Earlier obesity trials without diabetes recorded side effects including nausea and diarrhea. The drug now stands headed for FDA review as clinical testing advances.

    What is confirmed

    • Eli Lilly developed retatrutide as an experimental once-weekly injection to treat obesity and type 2 diabetes.
    • Adults with obesity but no diabetes lost up to 25 percent of their body weight on weekly retatrutide over 80 weeks compared to 3.9 percent on placebo.
    • The drug targets three hormone pathways simultaneously, which accelerates caloric expenditure.

    Still unconfirmed

    • Retatrutide is headed for FDA review as a triple-agonist weight loss drug.

    What to watch next

    • Upcoming regulatory review decisions by the FDA
    • Further data releases from the TRIUMPH trial series
    Sources used for this update (4)
    1. theindianpractitioner.com — Retatrutide Shows Significant Weight Loss in People with ...
    2. fitnesshealthandnutrition.com — Retatrutide: 25% Weight Loss at 80 Weeks in Phase 3 Trial
    3. biologyinsights.com — Retatrutide Clinical Trials: Triple Hormone Targeting Updates
    4. www.clarin.com — What is retatrutide? Everything to know about 'RETA,' the ...
    confidence 100%
  5. Eli Lilly's Retatrutide Trial Shows Deep Weight Loss in Type 2 Diabetes

    Eli Lilly's experimental triple-hormone drug retatrutide cut body weight by 20.8 percent in a Phase 3 trial for adults with Type 2 diabetes over 80 weeks, while also improving blood sugar control. The once-weekly injection activates three hormone receptors at once, setting it apart from single-hormone treatments like semaglutide and dual-hormone options like tirzepatide. Previous data from the TRIUMPH-1 trial showed a 25.0 percent weight loss for adults with obesity without diabetes at the same dose and duration, alongside more nausea and diarrhea.

    Why it matters

    Retatrutide is an experimental once-weekly injection developed by Eli Lilly to treat obesity and type 2 diabetes simultaneously. Clinical evaluations continue to test its efficacy and safety at various doses, with patients on the lowest dose losing 12.7 percent of their body weight. The drug's unique triple-receptor activation mechanism has drawn intense interest across both the pharmaceutical and bodybuilding sectors.

    What is confirmed

    • Retatrutide cut body weight by 20.8 percent in a Phase 3 Type 2 diabetes trial.
    • Trial participants with type 2 diabetes lost 20.8 percent of their body weight after receiving 12 mg of retatrutide for 80 weeks in the TRIUMPH-2 study.
    • Previous data from the TRIUMPH-1 trial showed a 25.0 percent weight loss for adults with obesity without diabetes at the same dose and duration.

    Still unconfirmed

    • Retatrutide could help tackle obesity and type 2 diabetes together, with an 80-week trial showing substantial weight loss and better blood sugar control alongside more nausea and diarrhea.

    What to watch next

    • Release of additional dosage tier results from the TRIUMPH clinical trial program.
    • Regulatory filings and timelines for commercial availability by Eli Lilly.
    Sources used for this update (10)
    1. theprimary.com — Experimental triple hormone drug reduces body weight in ...
    2. jen.jiji.com — 'Belve' returns with a new season, from November 24th on Rai2 in prime time
    3. scitechdaily.com — Beyond Ozempic? New Weight Loss Drug Shows Stunning Results ...
    4. www.finanznachrichten.de — Eli Lilly and Company: Lilly's triple agonist, retatrutide ...
    5. jaycampbell.com — Retatrutide, Part 2: Examining The Scientific Evidence ...
    6. medicalxpress.com — Triple-action drug retatrutide delivers major weight loss for ...
    7. jen.jiji.com — Pakistan, school roof collapses in Peshawar, 28 dead and 30 injured
    8. jen.jiji.com — Ukraine, Musk against Zelensky: "It's time for him to go". Kyiv resumes attacks on Russian refineries
    9. www.diabetes.co.uk — Retatrutide delivers 18.8% average weight loss in Phase III ...
    10. www.newsweek.com — When Could Reta Be Available? Weight-Loss Drug Retatrutide ...
    confidence 95%
  6. Retatrutide Trials Show Significant Weight Loss in Diabetes

    Trial participants with type 2 diabetes lost 20.8 percent of their body weight after receiving 12 mg of retatrutide for 80 weeks in the TRIUMPH-2 study. Previous data from the TRIUMPH-1 trial showed a 25.0 percent weight loss for adults with obesity without diabetes at the same dose and duration, while Lancet results showed 23.4 percent weight loss in adults with type 2 diabetes and a body mass index of 35 or higher. Additional data indicate that patients taking the lowest dose of the drug lost 12.7 percent of their body weight.

    Why it matters

    Retatrutide functions as a triple agonist targeting GLP-1, GIP, and glucagon receptors, producing dose-dependent weight loss and HbA1c reduction in obesity and type 2 diabetes studies. Eli Lilly develops the experimental drug, which has demonstrated substantial efficacy in Phase 3 clinical evaluations. Despite these clinical results, the treatment has not yet received FDA approval.

    What is confirmed

    • Data from the TRIUMPH-2 study showed that participants who received 12 mg of the drug for 80 weeks lost 20.8 percent of their body weight.

    What to watch next

    • Future decisions by the FDA regarding the approval of retatrutide.
    Sources used for this update (4)
    1. www.zmescience.com — New Weight-Loss Drug Helps People With Type 2 Diabetes Lose 21% of Their Body Weight
    2. amplehealthandwellness.com — Retatrutide Use After 40: What Women Should Know About the ...
    3. gpnotebook.com — Retatrutide – GPnotebook
    4. jen.jiji.com — Ranucci on no to reinstatement at Report: "I respect the judge's ruling but against me, mud to erase history"
    confidence 100%
  7. Retatrutide Trials Show Up to 25% Weight Loss

    Eli Lilly's experimental triple-hormone-receptor agonist retatrutide demonstrates substantial weight loss efficacy in recent clinical evaluations. Data from the TRIUMPH-1 phase 3 trial indicate that a 12-milligram weekly dose of retatrutide taken for 80 weeks produced an average weight loss of 25.0 percent in adults with obesity but without diabetes, compared to 3.9 percent for the placebo group. Meanwhile, full Lancet results show 23.4 percent weight loss in adults with type 2 diabetes and a body mass index of 35 or higher. Additional data show that patients taking the lowest dose of retatrutide lost 12.7 percent of their body weight.

    Why it matters

    Retatrutide belongs to the second wave of obesity medicines, targeting GLP-1, GIP, and glucagon metabolic receptors. As a next-generation treatment, it expands upon earlier single and dual agonist medications like semaglutide and tirzepatide. The drug is currently unapproved by regulators.

    What is confirmed

    • Twelve milligrams of retatrutide injected weekly for 80 weeks produced an average weight loss of 25.0 percent in adults with obesity without diabetes, compared to 3.9 percent on placebo.
    • Retatrutide averaged 28.3 percent weight loss at 80 weeks in Lilly's TRIUMPH-1 trial.
    • Full Lancet results show 23.4 percent weight loss in adults with type 2 diabetes and a body mass index of 35 or higher.
    • Patients taking the lowest dose of Eli Lilly's experimental retatrutide lost 12.7 percent of their body weight.

    Still unconfirmed

    • Retatrutide's FDA filing is planned for the first quarter of 2027.

    What to watch next

    • Eli Lilly's planned FDA filing for retatrutide in the first quarter of 2027
    • Regulatory decisions regarding next-generation obesity therapies
    Sources used for this update (7)
    1. www.onedaymd.com — GLP-1 Studies Explained: The Complete Evidence Guide (2026 ...
    2. www.medicaldaily.com — Peer-Reviewed Retatrutide Data Show 23.4% Weight Loss in ...
    3. www.onedaymd.com — GLP-1 2.0: The Next Generation of Obesity Drugs - onedaymd.com
    4. www.fool.com — Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be ...
    5. morningoverview.com — Retatrutide took 25% off body weight at its top dose
    6. www.yahoo.com — Ozempic Rival Delivers 25% Weight Loss at Highest Dose in ...
    7. businessdailymedia.com — Triple agonist UBT251 delivers up to 19.7% mean weight loss ...
    confidence 95%
  8. Doctors Prescribe GLP-1s to Children Amid Broad Obesity Drug Expansion

    Doctors are prescribing GLP-1 medications to children for weight loss as the usage of these treatments expands across different demographics. Clinical studies previously showed that patients taking the lowest dose of Eli Lilly's experimental triple-hormone-receptor agonist retatrutide lost 12.7 percent of their body weight. The drug targets three metabolic receptors including GLP-1, GIP, and glucagon, establishing it as a next-generation obesity treatment. Across clinical evaluations, average weight loss reached about 50 pounds in certain contexts. Additionally, Eli Lilly reported data on combination regimens like EloraTZP, showing greater weight loss and A1C reduction compared to existing therapies in adults with obesity and type 2 diabetes.

    Why it matters

    The expanding market for anti-obesity medications increasingly involves pediatric populations as prescription trends widen. Pharmaceutical developers continue to test multi-receptor agonist therapies that target hormonal pathways beyond standard single-receptor treatments. These developments raise critical questions regarding long-term safety, pediatric dosing parameters, and therapeutic guidelines for younger patients.

    What is confirmed

    • Doctors are prescribing children GLP-1s for weight loss.

    What to watch next

    • Further clinical trial results for retatrutide and combination regimens like EloraTZP
    • Regulatory decisions regarding the approval of GLP-1 medications for pediatric patients
    • Additional guidance from medical boards on prescribing anti-obesity drugs to children
    Sources used for this update (9)
    1. politifact.com — Weight loss GLP-1s are everywhere and kids are taking them too. 7 things parents should know
    2. twominenglish.com — Triple vs Tripple – Which is Correct? - Two Minute English
    3. dictionary.cambridge.org — TRIPLE | English meaning - Cambridge Dictionary
    4. dictionary.cambridge.org — TRIPLE | definition in the Cambridge English Dictionary
    5. tripleseat.com — Tripleseat | All-in-One Event Venue Management Software
    6. www.dictionary.com — TRIPLE Definition & Meaning | Dictionary.com
    7. en.wikipedia.org — Triple - Wikipedia
    8. www.vocabulary.com — Triple - Definition, Meaning & Synonyms | Vocabulary.com
    9. www.definitions.net — What does triple mean? - Definitions.net
    confidence 90%
  9. Eli Lilly Triple-G Trial Shows 12.7% Weight Loss On Lowest Dose

    Trial patients taking the lowest dose of Eli Lilly's experimental triple-hormone-receptor agonist retatrutide lost 12.7 percent of their body weight, according to recent updates from clinical studies. The drug targets three metabolic receptors including GLP-1, GIP, and glucagon, earning it the label of a next-generation obesity treatment. Across clinical evaluations, the drug has delivered substantial reductions, with average weight loss reaching about 50 pounds in certain contexts. Additionally, Eli Lilly reported data on combination regimens like EloraTZP, showing greater weight loss and A1C reduction compared to existing therapies in adults with obesity and type 2 diabetes.

    Why it matters

    Retatrutide represents an evolution in cardiometabolic drug development by attacking multiple biological pathways simultaneously rather than relying on single-receptor mechanisms. Eli Lilly expects to submit the treatment to the Food and Drug Administration for approval early next year as clinical trials draw to a close. These advancements build upon earlier successes of GLP-1 medications, pushing efficacy boundaries further for patients managing obesity and type 2 diabetes.

    What is confirmed

    • Patients on the lowest dose of Eli Lilly's triple-G drug retatrutide lost 12.7 percent of their weight in trial evaluations.
    • Retatrutide is the first drug of its kind to target three metabolic receptors, specifically GLP-1, GIP, and glucagon.
    • Eli Lilly plans to submit retatrutide to the FDA for approval early next year as clinical trials conclude.
    • Lilly's EloraTZP combination of eloralintide and tirzepatide delivered greater weight loss and A1C reduction compared to tirzepatide 15 mg in adults with obesity and type 2 diabetes.

    Still unconfirmed

    • Retatrutide delivers an average weight loss of 50 pounds.

    What to watch next

    • Submission of retatrutide to the FDA for approval early next year
    • Further disclosure of late-stage clinical trial data by Eli Lilly
    Sources used for this update (11)
    1. The Guardian — ‘Godzilla’ of weight-loss drugs could provide other important health benefits
    2. CNBC — Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
    3. Eli Lilly — Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
    4. Reuters — Experimental Lilly combination drug tops Zepbound in weight-loss trial
    5. USA Today — Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
    6. New York Post — ‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight
    7. New Scientist — ‘Astonishing’ weight loss when GLP-1 drug used with second medication
    8. nypost.com — Even on the lowest dose of 'triple G' drug patients lost ...
    9. WSJ — Lilly’s Next-Gen Obesity Drug Helps People Lose Even More Weight in Study
    10. jen.jiji.com — Timofeeva and the watch stolen in the locker room: "I had left it unattended for 10 minutes..."
    11. pharmaphorum.com — Lilly fleshes out triple G data in diabetes and obesity
    confidence 95%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community